Gwenn M. Hansen, Ph.D., serves as the Chief Scientific Officer at Nurix Therapeutics, Inc., a biopharmaceutical company focused on the discovery and development of novel therapies for cancer and other challenging diseases. Dr. Hansen has been instrumental in steering Nurix's scientific strategy since joining the company in 2014. With a robust background in biochemistry and molecular biology, she has over two decades of experience in drug discovery and development, particularly in the areas of targeted protein degradation and immunology. Prior to her role at Nurix, Dr. Hansen held significant positions at leading biotech firms, including Amgen and Kalypsys, where she honed her skills in leading research teams and advancing therapeutic programs from discovery through clinical development. Her work has contributed to the development of several drug candidates, showcasing her ability to translate complex scientific concepts into viable medical solutions. At Nurix, Dr. Hansen oversees the company's research and development efforts, guiding the advancement of its pipeline of innovative drug candidates that leverage the body's natural protein degradation processes to treat diseases. Under Dr. Hansen's leadership, Nurix has made significant strides in the field of targeted protein degradation, a cutting-edge approach that has the potential to revolutionize treatment options for patients. Her strategic vision and scientific expertise have been pivotal in securing partnerships with major pharmaceutical companies and in advancing Nurix's proprietary platforms. Dr. Hansen's contributions to the field have been recognized through numerous publications and presentations at scientific conferences, solidifying her reputation as a leader in the biopharmaceutical industry.